Kynurenine pathway abnormalities in Parkinson's disease.
about
Kynurenines in CNS disease: regulation by inflammatory cytokinesModulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brainEmerging preclinical pharmacological targets for Parkinson's diseaseTargeting New Candidate Genes by Small Molecules Approaching Neurodegenerative DiseasesIndoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's DiseaseKynurenines in the mammalian brain: when physiology meets pathologyStructure, expression, and function of kynurenine aminotransferases in human and rodent brainsChanging the face of kynurenines and neurotoxicity: therapeutic considerationsL-NAME reverses quinolinic acid-induced toxicity in rat corticostriatal slices: Involvement of src family kinasesTryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolitesKynurenines in chronic neurodegenerative disorders: future therapeutic strategiesMetabolomics and the search for biomarkers in Parkinson's diseaseSystemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice.The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis inductionCSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.Novel therapeutic strategies in Parkinson's disease.Crystallographic and spectroscopic snapshots reveal a dehydrogenase in action.Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.Reduced plasma concentrations of vitamin B6 and increased plasma concentrations of the neurotoxin 3-hydroxykynurenine are associated with nodding syndrome: a case control study in Gulu and Amuru districts, Northern UgandaHydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine.Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lensPharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases.Fenpropathrin, a Widely Used Pesticide, Causes Dopaminergic Degeneration.Kynurenines in Parkinson's disease: therapeutic perspectives.Understanding the roles of the kynurenine pathway in multiple sclerosis progression.Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors.Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease researchChanges in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.Major developments in the design of inhibitors along the kynurenine pathway.Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.Glial biomarkers in human central nervous system disease.Astrocytic and neuronal localization of kynurenine aminotransferase-2 in the adult mouse brain.
P2860
Q21129356-5A386864-2BAE-4EE0-BD4D-C35A47BAE798Q24564986-874754CE-282F-4088-9D41-AAD9F44A03D8Q26764724-77E60AB3-D11A-44BC-A297-FCE341774581Q26771812-0862672E-BC24-4807-AA21-6E588D613387Q26781849-9D786BCA-5373-48CC-A7F2-B57CB46DAE5EQ27003296-A6D67831-8E66-4920-AED3-7C743BE443B9Q27657768-E6B8FBE6-8C11-4008-8A63-ED41C85FB9AEQ28085041-F113C9AD-F695-40C9-80E4-E88CA2194AC9Q28568299-FC9BB761-DD4A-4E79-822B-2D995DB13D12Q28834131-DF4E80B5-0546-4CA7-9DF5-15A6257C086BQ29398467-FB7792E8-4A86-4DF2-818A-DC0448553268Q30410511-CD624F88-B5A8-4CCC-8878-5FE1B3888A84Q30654478-2D8E91D3-8054-4920-9DDB-6A892B3D533CQ30977301-74DCADC5-3991-4485-ACA6-DD7D94B34A5BQ33994583-1B96082D-7265-4140-BB15-BDB2E266C662Q34612832-4F50E02A-321C-44A6-B588-E7D2C34EA7DDQ34865894-B9FDD026-4799-428A-B901-8A4E351C98BAQ34979782-5056C707-F70E-4BC7-8D54-9C71E93F7401Q35029070-036FDA4A-1E67-42CE-975E-913E32FB12F8Q35366778-C31343C8-9002-4694-B4BE-9DC72FE44827Q35554351-38F3AE9B-6A06-4D4A-AB23-C5F5B9C2F7DAQ37234947-B0B523AB-D932-4B21-846A-57C27A08C512Q37242921-3D9456D8-80DC-472D-BB45-D49CF639D7D3Q37293658-086138C9-FE0B-4F5C-AA6F-28F355CC7D0FQ37378691-04A366D5-8733-40C4-843B-57C606012FF6Q37580731-4AED2826-9BD9-464B-AA61-E1E8E371BF4EQ37623378-BD5A9C18-5F7C-44E4-8DC5-72826C30FC86Q37677250-3EED296F-718A-4C73-9FDA-0361984A4BD3Q37920750-222C00CF-179D-423C-8C8A-3013522697F0Q37956307-3E92DADB-208E-438F-9774-5C37B8E8DDB7Q38063779-0D640992-DD22-46F6-8950-AFC0E20FC1D4Q38103448-E6179891-0D7B-411B-B1A5-F19B918C09E9Q38150700-5FEA7CE0-DB7E-4C2C-A628-DD015492F313Q38171958-4654B5A1-C872-445D-8062-090A905ED827Q38268639-FDC95780-BEE9-4C14-9A22-0EA6A3F966C2Q38719357-A11FC88E-0267-4BC1-A1C4-21EA1FCEE755Q38808400-856A878D-54FF-4B1F-84F5-93A448E7E512Q38843539-88A04284-67ED-4CE4-B922-86D63DCB0274Q38845041-E4763E4C-8F6E-49B6-84D2-5DBB398555F7Q39446439-85418B42-FF8F-4BF9-AA16-5A619E76AB5D
P2860
Kynurenine pathway abnormalities in Parkinson's disease.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Kynurenine pathway abnormalities in Parkinson's disease.
@en
Kynurenine pathway abnormalities in Parkinson's disease.
@nl
type
label
Kynurenine pathway abnormalities in Parkinson's disease.
@en
Kynurenine pathway abnormalities in Parkinson's disease.
@nl
prefLabel
Kynurenine pathway abnormalities in Parkinson's disease.
@en
Kynurenine pathway abnormalities in Parkinson's disease.
@nl
P2093
P356
P1433
P1476
Kynurenine pathway abnormalities in Parkinson's disease.
@en
P2093
P304
P356
10.1212/WNL.42.9.1702
P407
P577
1992-09-01T00:00:00Z